CS-1 peptidomimetics, compositions and methods of using same

Details CS-1 peptidomimetics, compositions and methods of using same CS-1 peptidomimetics, compositions and methods of using same

1995-06-05

1998-10-13

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 19, 5142275, 5142312, 514255, 514277, 514386, 514392, 530331, A61K 3805, A61K 3806, C07K 504

Patent

active

058212310

ABSTRACT:
The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.

REFERENCES:
patent: 4564616 (1986-01-01), Jones et al.
patent: 4822606 (1989-04-01), Snyderman et al.
patent: 5294511 (1994-03-01), Furcht et al.
patent: 5294551 (1994-03-01), Furcht et al.
patent: 5340802 (1994-08-01), Shiosaki et al.
patent: 5387504 (1995-02-01), Mumford
Esser et al., "N-terminale Cyclisierung Von Peptiden mit N, N' Carbonyldimidazole oder N, N'-thiocarbonyldimidazol", Agnew. Chem. 1978, vol. 90, No. 6, pp. 495-496.
Mould et al., "The CS5 Peptide Is a Second Site in the IIICS Region of Fibronectin Recognized by the Integrin .alpha..sub.4 .beta..sub.1 " J. of Biol. Chem., vol. 266, No. 6, pp. 3579-3585, Feb. 25, 1991.
Esser, F. and Roos, O. "N-Terminal Cyclization of Peptides with N,N'-Carbonyldiimidazole or N,N'-Thiocarbonyldiimidazole." Angew. Chem. Int. Ed. Engl. 17(6):467-468 (1978).
Komoriya, Akira et al., "The Minimal Essential Sequence for a Major Cell Type-Specific Adhesion Site (CS1) Within the Alternatively Splice Type III Connecting Segment Domain of Fibronectin is Leucine-Aspartic Acid-Valine." J. Biol. Chem. 266:15075-15079 (1991).
Elices, Mariano "The Integrin .alpha..sub.4 .beta..sub.1 (VLA-4) as a Therapeutic Target." Cell Adhesion and Human Disease. Wiley, Chichester (Ciba Foundation Symposium 189) pp. 79-90 (1995).
Nowlin, Dawn M., "A Novel Cyclic Pentapeptide Inhibits .alpha.4.beta.1 and .alpha.5.beta.1 Integrin-mediated Cell Adhesion." J. Biol. Chem. 268:20352-20359 (1993).
Mousa, Shaker A. et al., "Antiplatelet Efficacy and Specificity of DMP728, a Novel Platelet GPllB/IIIa Receptor Antagonist." Clin. Pharm. 83:373-382 (1993).
Cardarelli, Pina et al., "Cyclic RGD Peptide Inhibits .alpha.4.beta.1 Interaction with Connecting Segment 1 and Vascular Cell Adhesion Molecule." J. Biol. Chem. 269:18668-18673 (1994).
Pfaff, Martin et al., "Seletive Recognition of Cyclic RGD Peptides of NMR Defined Conformation by .alpha.V.beta.3, .alpha.5.beta.1 Integrins." J. Biol. Chem. 269:20233-20238 (1994).

Affiliated with

Also associated with

Rating

CS-1 peptidomimetics, compositions and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CS-1 peptidomimetics, compositions and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CS-1 peptidomimetics, compositions and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-313324